Law Office of Brodsky & Smith, LLC Announces Investigation of Anadys Pharmaceticals, Inc.
19 Octobre 2011 - 5:30AM
Business Wire
Law office of Brodsky & Smith, LLC announces that it is
investigating potential claims against the Board of Directors of
Anadys Pharmaceticals, Inc. (“Anadys” or the “Company”) (Nasdaq:
ANDS) relating to the proposed acquisition Roche Holding AG.
(“Roche”).
Under the terms of the transaction Anadys shareholders would
receive $3.70 in cash for each share of Anadys stock they own. The
investigation concerns possible breaches of fiduciary duty and
other violations of state law by the Board of Directors of Anadys
for not acting in the Anadys shareholders' best interests in
connection with the sale process to Roche. The transaction may
undervalue the Company as an analyst has set a price target of
$4.00 for Anadys stock.
If you own shares of Anadys stock and wish to discuss the legal
ramifications of the proposed transaction, or have any questions,
you may e-mail or call the law office of Brodsky & Smith, LLC
who will, without obligation or cost to you, attempt to answer your
questions. You may contact Jason L. Brodsky, Esquire or Evan J.
Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite
602, Bala Cynwyd, PA 19004, by e-mail at
investorrelations@brodsky-smith.com, visiting
http://brodsky-smith.com/345-ands-anadys-pharmaceuticals-inc.html,
or by calling toll free 877-LEGAL-90.
Anadys (NASDAQ:ANDS)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Anadys (NASDAQ:ANDS)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024
Real-Time news about Anadys Pharmaceuticals (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Brodsky & Smith, LLC